Sam Sihvonen is the CEO of Solu - a precision genomics platform helping hospitals and institutions detect, prevent and control infections before they spread.What began as a diagnostics-focused tool has rapidly expanded across major verticals from food safety and agriculture to pharma, industrial bio and research. Sam and the team believe Solu can become a company that reshapes how we identify and stop infectious threats in the real world.From the economics of drug development, to the global risk of antibiotic resistance, Sam explains why the world urgently needs better tools - and why Solu is already making a measurable impact.Chapters:00:00 Intro01:12 Big verticals in genomics01:42 Why this could become a massive company02:25 The Slush talk with Enveda03:10 Why biotech execution is so hard04:05 Why no $1T biotech exists (yet)04:50 Drug development timelines + costs05:32 The antibiotic crisis06:21 What success looks like for Solu08:02 Early customers + real-world usage08:45 Advice to early-stage founders09:18 Raising the ceiling on your ambition10:02 How Slush drives bigger thinkingHuge thanks to Sam for making the time!#foundersandbuilders #samsihvonen #solu